The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Three Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis
Open accessAbstract
Objective: To evaluate the efficacy and safety of ustekinumab in 3 randomized, placebo‐controlled studies in patients with axial spondyloarthritis (SpA). Studies 1 and 2 included patients with radiographic axial SpA (anti–tumor necrosis factor [anti‐ TNF ]–naive patients and patients with inadequate response or intolerance to anti‐ TNF , respectively); study 3 patients had nonradiographic axial SpA. Methods: In all 3 studies, patients were randomly assigned (1:1:1) to receive subcutaneous ustekinumab at 45 mg or 90 mg or placebo up to 24 weeks, after which placebo‐treated patients were rerandomized to receive ustekinumab at 45 mg or 90 mg. The primary end point in studies 1 and 2 was the proportion of patients who met the Assessment of SpondyloArthritis international Society criteria for 40% improvement in disease activity (achieved an ASAS 40 response). The primary end point in study 3 was the proportion of patients who achieved an ASAS 20 response. Other disease activity and safety measures were also evaluated. A week 24 analysis of study 1 was preplanned to determine continuation of studies 2 and 3. Results: For study 1, the primary and major secondary end points were not met, and the study was discontinued. As a result, studies 2 and 3 were prematurely discontinued before they were fully enrolled. For all 3 studies, neither ustekinumab dose group demonstrated clinically meaningful improvement over placebo on key efficacy end points. The proportion of patients experiencing adverse events in the ustekinumab groups was consistent with that in previous studies. Conclusion: In these 3 placebo‐controlled trials, efficacy of ustekinumab in the treatment of axial SpA was not demonstrated. The safety profile was consistent with that of studies in other indications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evaluation of Diagnostic Criteria for Ankylosing Spondylitis
Linden, S. V. D., Valkenburg, H. A., & Cats, A. (1984) · Arthritis & Rheumatism · doi:10.1002/art.1780270401 · Cited by 5,697
Rudwaleit, M., van der Heijde, D., Landewé, R., Listing, J., Akkoc, N., Brandt, J., Braun, J., Chou, C. T., Collantes-Estevez, E., Dougados, M., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.108233 · Cited by 3,690
Self-citationGarrett, S., Jenkinson, T., Kennedy, L. G., Whitelock, H., Gaisford, P., & Călin, A. (1994) · PubMed · Cited by 3,241
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
Sandborn, W. J., Feagan, B. G., Rutgeerts, P., Hanauer, S., Colombel, J.-F., Sands, B. E., Lukas, M., Fedorak, R. N., Lee, S., Bressler, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215739 · Cited by 2,719
Leonardi, C. L., Kimball, A. B., Papp, K. A., Yeilding, N., Guzzo, C., Wang, Y., Li, S., Dooley, L. T., & Gordon, K. B. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60725-4 · Cited by 1,874
Self-citationUstekinumab as Induction and Maintenance Therapy for Crohn’s Disease
Feagan, B. G., Sandborn, W. J., Gasink, C., Jacobstein, D., Lang, Y., Friedman, J. R., Blank, M. A., Johanns, J., Gao, L.-L., Miao, Y., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602773 · Cited by 1,845
Călin, A., Garrett, S., Whitelock, H., Kennedy, L. G., O'Hea, J., MALLORIE, P. A., & Jenkinson, T. (1994) · PubMed · Cited by 1,834
(2001) · Classic Papers in Rheumatology · doi:10.3109/9780203214237-70 · Cited by 1,833
Sieper, J., Rudwaleit, M., Baraliakos, X., Brandt, J., Braun, J., Burgos-Vargas, R., Dougados, M., Hermann, K.-G., Landewé, R., Maksymowych, W., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.104018 · Cited by 1,652
Self-citationAssociation scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants
Wellcome Trust Case Control Consortium, & The Australo-Anglo-American Spondylitis Consortium (TASC) (2007) · Nature Genetics · doi:10.1038/ng.2007.17 · Cited by 1,374
Papp, K. A., Langley, R. G., Lebwohl, M., Krueger, G. G., Szapary, P., Yeilding, N., Guzzo, C., Hsu, M.-C., Wang, Y., Li, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60726-6 · Cited by 1,361
Self-citationSieper, J., & Poddubnyy, D. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31591-4 · Cited by 1,333
Self-citationIL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4−CD8− entheseal resident T cells
Sherlock, J. P., Joyce-Shaikh, B., Turner, S. P., Chao, C.-C., Sathe, M., Grein, J., Gorman, D. M., Bowman, E. P., McClanahan, T. K., Yearley, J. H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2817 · Cited by 1,060
Psoriasis pathogenesis and the development of novel targeted immune therapies
Hawkes, J. E., Chan, T. C., & Krueger, J. G. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.07.004 · Cited by 972
Rudwaleit, M., Jurik, A. G., Hermann, K.-G. A., Landewé, R., van der Heijde, D., Baraliakos, X., Marzo-Ortega, H., Østergaard, M., Braun, J., & Sieper, J. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.110767 · Cited by 902
Self-citationMcInnes, I. B., Kavanaugh, A., Gottlieb, A. B., Puig, L., Rahman, P., Ritchlin, C., Brodmerkel, C., Li, S., Wang, Y., Mendelsohn, A. M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60594-2 · Cited by 807
Self-citationMachado, P., Landewé, R., Lie, E., Kvien, T. K., Braun, J., Baker, D., & van der Heijde, D. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.138594 · Cited by 805
Self-citationInterleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability
Lee, J. S., Tato, C. M., Joyce-Shaikh, B., Gulen, M. F., Cayatte, C., Chen, Y., Blumenschein, W. M., Judo, M., Ayanoglu, G., McClanahan, T. K., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.09.003 · Cited by 760
Ritchlin, C., Rahman, P., Kavanaugh, A., McInnes, I. B., Puig, L., Li, S., Wang, Y., Shen, Y.-K., Doyle, M. K., Mendelsohn, A. M., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204655 · Cited by 662
Self-citationSieper, J., van der Heijde, D., Landewé, R., Brandt, J., Burgos-Vagas, R., Collantes-Estevez, E., Dijkmans, B., Dougados, M., Khan, M. A., Leirisalo-Repo, M., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.101501 · Cited by 654
Self-citationAnderson, J. J., Baron, G., Van Der Heijde, D., Felson, D. T., & Dougados, M. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200108)44:8<1876::aid-art326>3.0.co;2-f · Cited by 606
Self-citationBaeten, D., Baraliakos, X., Braun, J., Sieper, J., Emery, P., van der Heijde, D., McInnes, I., van Laar, J. M., Landewé, R., Wordsworth, P., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61134-4 · Cited by 595
Self-citationShen, H., Goodall, J. C., & Hill Gaston, J. S. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24568 · Cited by 516
Landewé, R., Braun, J., Deodhar, A. A., Dougados, M., Maksymowych, W. P., Mease, P. J., Reveille, J. D., Rudwaleit, M., van der Heijde, D. M. F. M., Stach, C. M., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204231 · Cited by 470
Self-citationvan der Heijde, D., Sieper, J., Maksymowych, W. P., Dougados, M., Burgos-Vargas, R., Landewé, R., Rudwaleit, M., & Braun, J. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2011.151563 · Cited by 412
Self-citationJandus, C., Bioley, G., Rivals, J., Dudler, J., Speiser, D., & Romero, P. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23655 · Cited by 382
Differential Roles for Interleukin-23 and Interleukin-17 in Intestinal Immunoregulation
Maxwell, J. R., Zhang, Y., Brown, W. A., Smith, C. L., Byrne, F. R., Fiorino, M., Stevens, E., Bigler, J., Davis, J. A., Rottman, J. B., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.08.019 · Cited by 342
Appel, H., Maier, R., Wu, P., Scheer, R., Hempfing, A., Kayser, R., Thiel, A., Radbruch, A., Loddenkemper, C., & Sieper, J. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3370 · Cited by 313
Self-citationPathogenesis of ankylosing spondylitis — recent advances and future directions
Ranganathan, V., Gracey, E., Brown, M. A., Inman, R. D., & Haroon, N. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.56 · Cited by 311
Kavanaugh, A., Ritchlin, C., Rahman, P., Puig, L., Gottlieb, A. B., Li, S., Wang, Y., Noonan, L., Brodmerkel, C., Song, M., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204741 · Cited by 295
Self-citationPoddubnyy, D., Hermann, K.-G. A., Callhoff, J., Listing, J., & Sieper, J. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204248 · Cited by 260
Self-citationHLA-B27 misfolding and ankylosing spondylitis
Colbert, R. A., Tran, T. M., & Layh-Schmitt, G. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2013.07.013 · Cited by 228
Contribution of the IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease
Cătană, C.-S., Neagoe, I. B., Cozma, V., Magdaş, C., Tăbăran, F., & Dumitraşcu, D. L. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i19.5823 · Cited by 183
Braun, J., Baraliakos, X., Golder, W., Hermann, K.-G., Listing, J., Brandt, J., Rudwaleit, M., Zuehlsdorf, S., Bollow, M., Sieper, J., et al. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.019968 · Cited by 175
Self-citationKavanaugh, A., Puig, L., Gottlieb, A. B., Ritchlin, C., You, Y., Li, S., Song, M., Randazzo, B., Rahman, P., & McInnes, I. B. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-209068 · Cited by 162
Appel, H., Maier, R., Bleil, J., Hempfing, A., Loddenkemper, C., Schlichting, U., Syrbe, U., & Sieper, J. (2013) · Arthritis & Rheumatism · doi:10.1002/art.37937 · Cited by 147
Self-citationInflammatory pathways in spondyloarthritis
Hreggvidsdottir, H. S., Noordenbos, T., & Baeten, D. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2013.07.016 · Cited by 136
Association between Th-17 cytokine profile and clinical features in patients with spondyloarthritis.
Romero‐Sánchez, C., Jaimes, D. A., Londoño, J. D., Ávila, J. D., Castellanos, J. E., Bello, J., Bautista, W., & Valle‐Oñate, R. (2011) · PubMed · Cited by 45
Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis
Alunno, A., Carubbi, F., Cafaro, G., Pucci, G., Battista, F., Bartoloni, E., Giacomelli, R., Schillaci, G., & Gerli, R. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1084284 · Cited by 41
Comorbidities in Patients with Spondyloarthritis
van der Horst-Bruinsma, I. E., Nurmohamed, M. T., & Landewé, R. (2012) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2012.08.010 · Cited by 39
Cited by
Coates, L. C., Soriano, E. R., Corp, N., Bertheussen, H., Callis Duffin, K., Campanholo, C. B., Chau, J., Eder, L., Fernández-Ávila, D. G., FitzGerald, O., et al. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00798-0 · Cited by 627
Ankylosing spondylitis: etiology, pathogenesis, and treatments
Zhu, W., He, X., Cheng, K., Zhang, L., Chen, D., Wang, X., Qiu, G., Cao, X., & Weng, X. (2019) · Bone Research · doi:10.1038/s41413-019-0057-8 · Cited by 502
FitzGerald, O., Ogdie, A., Chandran, V., Coates, L. C., Kavanaugh, A., Tillett, W., Leung, Y. Y., deWit, M., Scher, J. U., & Mease, P. J. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00293-y · Cited by 367
Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs
Schett, G., McInnes, I. B., & Neurath, M. F. (2021) · New England Journal of Medicine · doi:10.1056/nejmra1909094 · Cited by 355
Navarro-Compán, V., Sepriano, A., El-Zorkany, B., & van der Heijde, D. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-221035 · Cited by 340
Self-citation
Metadata
- Authors
- Deodhar, A., Gensler, L. S., Sieper, J., Clark, M., Calderon, C., Wang, Y., Zhou, Y., Leu, J. H., Campbell, K., Sweet, K., Harrison, D. D., Hsia, E. C., & van der Heijde, D.
- Venue
- Arthritis & Rheumatology
- Publisher
- Wiley
- Published
- 2018-12-29
- Volume
- 71
- Issue
- 2
- Pages
- 258-270
- ISSN
- 2326-5191 (ISSN-L)
- 2326-5205
- OpenAlex
- W2891366322
- Cited by
- 334
- References
- 40
- FWCI
- 28.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.